On June 8, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that six abstracts have been accepted for presentation at European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress, taking place June 11 – 14 in Stockholm, Sweden. As Europe’s premier congress for hematology, the annual EHA (Free EHA Whitepaper) meeting brings together world-leading clinicians and researchers to share medical breakthroughs in the diagnosis, treatment, and clinical management of blood disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations showcase how BostonGene’s platforms integrate clinical, genomic, and immune data to uncover critical disease mechanisms. Conducted in collaboration with leading institutions, including Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, the University of Miami, and UT MD Anderson, this research demonstrates how integrated multiomics, predictive modeling, and high-dimensional blood immune system profiling can define resistance phenotypes to CAR-T therapies, identify unique immune states, and uncover deep remission pathways. These findings deliver actionable data that enable smarter patient selection, optimize frontline treatment decision-making, and enhance clinical trial design for blood cancers.

Details about the abstracts selected for presentation can be found below:

Oral presentation
Abstract: S283
Title: Integrated Multi-Omic Profiling Identifies Genomic Subtypes Associated with Differential Outcomes after CAR-T Therapy in Large B-Cell Lymphoma
Date & time: Saturday, June 13 | 18:00 – 18:15 CEST
Speaker: Silvia Escribano Serrat, MD, Memorial Sloan Kettering Cancer Center

Researchers at Memorial Sloan Kettering Cancer Center leveraged BostonGene’s multimodal computational pipeline, integrating molecular classifiers with gene signatures, to characterize mechanisms of CAR-T resistance in large B-cell lymphoma. Using the BostonGene Lymphly classifier, the BN2 subtype emerged as a high-risk group associated with significantly inferior survival and reduced response rates. Compared with existing frameworks, Lymphly provided improved stratification and clearer discrimination of outcome-relevant subgroups, underscoring the value of integrated molecular profiling for refining risk assessment following CAR-T.

Research conducted in collaboration with Memorial Sloan Kettering Cancer Center

Poster presentations

Abstract: PS2188
Title: Overlaying TP53 Loss and Aneuploidy with Distinct Diffuse Large B-Cell Lymphoma Subtypes Refines Tumor Classification and Enhances Risk Stratification
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Pavel Zemskiy, MS, BostonGene

BostonGene integrated two dimensions of genomic instability, TP53 loss‑of‑function alterations and quantitative aneuploidy, into Lymphly, a classification framework for diffuse large B‑cell lymphoma. This approach explicitly separates TP53 loss from aneuploidy, clarifying their independent and combined effects on tumor biology. By defining these mechanisms, the framework enables drug developers to anticipate and bypass resistance pathways, identify biomarker‑driven patient groups, and design trials aligned with genomic instability profiles.

Research conducted in collaboration with Center for Cancer Research

Abstract: PS1829
Title: Risk-Stratified Patient Selection in Multiple Myeloma for Frontline Treatment Decision-Making Based on a Transcriptomic Classifier
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Evgenia Alekseeva, PhD, BostonGene

BostonGene developed a transcriptomic-based risk stratification model to identify newly diagnosed multiple myeloma patients who may benefit from risk-adapted frontline treatment strategies, including aggressive regimens with bispecific T-cell engager (BiTE) and CAR T-cell therapies. This model outperformed conventional tools by isolating high-, intermediate-, and low-risk groups, while exposing high-risk cases with established resistance to proteasome inhibitors. Together, these findings define a biologically distinct high-risk state that may help prioritize patients for novel, more intensive treatment approaches earlier in the disease course.

Abstract: PS1854
Title: Peripheral Blood Immunoprofiling Defines Three Distinct Immune States Associated with Clinical and Molecular Axes in Multiple Myeloma
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Anastasia Radko, MS, BostonGene

BostonGene applied high‑dimensional flow cytometry to characterize peripheral blood immune architecture in multiple myeloma. Three coordinated immune states emerged, each aligned with cytogenetic risk, therapy exposure, and disease subtype. By defining these mechanisms, spanning T‑cell differentiation, checkpoint enrichment, and monocyte expansion, the framework enables drug developers to anticipate resistance, identify biomarker‑driven patient groups, and design trials that integrate circulating immune states into active therapeutic strategies.

Research conducted in collaboration with University of Miami

Abstract: PS2344
Title: Tazemetostat-Mediated Immune Remodeling in B-Cell Lymphomas Receiving CAR-T
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Samuel Yamshom, MD, Weill Cornell Medicine

BostonGene applied its multimodal molecular profiling platform to characterize the systemic immune remodeling driven by tazemetostat priming in patients with B-cell lymphomas receiving CART therapy. By integrating high-parameter flow cytometry, RNA sequencing, immune cell deconvolution, and functional gene signature analysis, BostonGene’s analysis revealed systemic immune remodeling associated with enhanced antigen presentation, T-cell activation, and reduced immunosuppressive signaling, validating the use of EZH2 inhibition for improved CART efficacy and durability.

Research conducted in collaboration with Weill Cornell Medicine

Abstract: PS1673
Title: Integrated Transcriptomic and Immune Profiling Identifies Determinants of Deep Remission with Ibrutinib–Venetoclax in Chronic Lymphocytic Leukemia
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Varsha Gandhi, PhD, UT MD Anderson

Leveraging BostonGene’s blood immunoprofiling platform and KassandraTM cell deconvolution, researchers at UT MD Anderson investigated the impact of ibrutinib–venetoclax combination therapy in patients with chronic lymphocytic leukemia. The findings revealed immune cell populations and gene expression patterns consistent with a common treatment resistance mechanism among patients who did not achieve remission. This study highlights BostonGene’s ability to harmonize clinical, genomic, transcriptomic, and immune data for reliable insights that drive smarter patient selection and optimized treatment decisions.

(Press release, BostonGene, JUN 8, 2026, View Source [SID1234666494])

On June 8, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial, which met its primary endpoint, demonstrating overall survival (OS) benefit in adult patients with previously treated recurrent or metastatic cervical cancer treated with TIVDAK compared to chemotherapy, including in an exploratory subpopulation of patients in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NMPA approval follows regulatory approvals in the United States, Japan, European Union, United Kingdom, Macau (China), and Hong Kong (China), underscoring the broad global clinical evidence supporting TIVDAK availability in China. The indication statement for TIVDAK differs slightly by region.

"Cervical cancer remains one of the leading causes of cancer death in women in China. Antibody-drug conjugates have proven to be novel and effective treatments for many types of cancer, and we are pleased to bring this innovative therapeutic class to patients in China with cervical cancer," said Rafael G. Amado, M.D., President and Head of Global Research and Development at Zai Lab. "Coupled with the previous global approvals of TIVDAK for this disease, the China BLA approval further validates the robust global evidence of clinical benefit for this population of advanced patients with limited therapeutic options."

Results from the Phase 3 innovaTV 301 clinical trial, including data from the China subpopulation of this study that Zai Lab conducted, supported global approval of TIVDAK:

In the global study, the trial met its primary endpoint of OS in the intention-to-treat (ITT) population of the global study (HR=0.70; 95% CI: 0.54–0.89; two-sided p=0.0038). The China subpopulation showed consistent results, with a clinically meaningful improvement in OS (HR: 0.55, 95% CI: 0.27- 1.15), corresponding to a 45% reduction in the risk of death compared to chemotherapy.1
54.1% of the China subpopulation received prior anti-PD(L)1 therapy, the current standard of care for second-line treatment of cervical cancer. TIVDAK showed consistent OS benefit trends irrespective of prior immunotherapy exposure.2
There were no new safety signals identified among patients in the China subpopulation who received TIVDAK. The most common Grade ≥3 treatment-emergent adverse events (TEAEs) in the global study were anemia (8.4%), urinary tract infection (4.4%), and abdominal pain (4.0%).1 The most common Grade ≥3 TEAEs in the China subpopulation were anemia (11.4%), cough (5.7%), and malaise (5.7%).2
"Treatment options are very limited for cervical cancer patients once recurrence or metastasis occurs," said Dr. Lingying Wu, Ph.D., China Leading Principal Investigator of the innovaTV 301 Study and Professor of the Department of Gynecologic Oncology of National Cancer Center / Cancer Hospital Chinese Academy of Medical Sciences. "Consistent with findings from the global innovaTV 301 trial, the China subpopulation data demonstrate that TIVDAK offers significant clinical benefits to these patients, irrespective of prior PD-(L)1 inhibitor therapy."

Zai Lab will leverage the company’s extensive experience and expanding presence in the Chinese gynecologic oncology community, as well as commercial synergies with its ZEJULA team, to bring TIVDAK to patients in China.

About Cervical Cancer in China

An estimated 150,000 new cases of cervical cancer occur annually in China3. Current treatment options are limited for patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is well positioned to provide a new option for previously treated advanced cervical cancer patients.

About Tisotumab Vedotin

Tisotumab vedotin (approved under the brand name TIVDAK in the EU, U.K., U.S. and Japan) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Pfizer’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. Nonclinical data suggest that the anticancer activity of tisotumab vedotin is due to the binding of the ADC to TF-expressing cancer cells, followed by internalization of the ADC-TF complex and release of MMAE via proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. In vitro, tisotumab vedotin also mediates antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity.

TIVDAK received full approval from the U.S. Food and Drug Administration in April 2024, and U.S. approval was first secured in September 2021 under the accelerated approval pathway for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Approval has also been received in Japan, European Union, Macau (China), and Hong Kong (China) for the same indication.

Zai Lab has an exclusive license from Seagen Inc., a company later acquired by Pfizer, for TIVDAK in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively). Zai Lab is solely responsible for the development, supply, and commercialization of TIVDAK in Greater China.

(Press release, Zai Laboratory, JUN 8, 2026, View Source [SID1234666493])

On June 8, 2026 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, reported that management will participate in Jones Trading’s Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.

(Press release, Compugen, JUN 8, 2026, View Source [SID1234666492])

On June 8, 2026 Hengrui Pharma reported more than 90 studies spanning multiple tumor types and therapeutic modalities at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world’s leading oncology conferences, the ASCO (Free ASCO Whitepaper) Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development..

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to statistics, 94 Chinese research projects were selected for oral presentations at ASCO (Free ASCO Whitepaper) this year, including 12 late-breaking abstracts, marking the third consecutive year of growth. At 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies, underscoring the breadth of the company’s oncology pipeline and ongoing investment in innovative drug development.

As a leading innovative pharmaceutical company in China, Hengrui continues to focus on oncology research and drug development. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO (Free ASCO Whitepaper) Annual Meeting. This year, the company’s research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification).

Breast Cancer: New Data Support Multiple Emerging Treatment Strategies

For triple-negative breast cancer, the HELEN-Trio 011 study led by Professor Zhenzhen Liu of Henan Cancer Hospital showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.

Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show Promise

In the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second Affiliated Hospital of Zhejiang University School of Medicine demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with standard-of-care (SOC), suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of hepatocellular carcinoma, the phase III CARES-336 trial, led by Academician Jia Fan (Zhongshan Hospital, Fudan University) and Professor Shukui Qin (Tsientang Institute for Advanced Study)—demonstrated that the combination of camrelizumab plus rivoceranib with transarterial chemoembolization (TACE) significantly improved median progression-free survival (PFS) versus TACE alone (11.1 vs. 8.3 months; BICR-assessed per mRECIST).This triplet regimen represents a new benchmark for systemic-combined locoregional therapy for patients with unresectable HCC (uHCC).

Urological Cancers: Dual Breakthroughs in Prostate and Bladder Cancers

The FUZUPRO study, led by Professor Dingwei Ye of Fudan University Shanghai Cancer Center, demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction.

Supportive Cancer Care: Additional Evidence for New Antiemetic Drug

The Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. These findings add to the growing body of clinical evidence supporting its use in supportive cancer care.

Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs.

Hengrui’s expanding presence at the ASCO (Free ASCO Whitepaper) Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company’s research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio.

As oncology research continues to evolve globally, Hengrui remains focused on translating scientific innovation into potential clinical benefit for patients through sustained investment in research and development.

(Press release, Hengrui Pharmaceuticals, JUN 8, 2026, View Source [SID1234666491])

On June 8, 2026 Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, reported that preclinical data for KT209, its novel trispecific antibody candidate, will be presented in a poster session at the European Hematology Association (EHA) (Free EHA Whitepaper) (EHA 2026) Annual Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to achieve deep B-cell depletion. While traditional bispecific T-cell engagers (TCEs) targeting a single antigen face challenges with treatment failure due to antigen escape (low or lost CD19/CD20 expression), KT209’s dual-antigen targeting mechanism is designed to prevent escape and improve clinical outcomes. Enhanced by a proprietary CD3 masking design, KT209 delivers exceptional anti-tumor potency alongside a highly optimized safety profile.

Presentation Details

Poster Title: A NOVEL TRISPECIFIC ANTIBODY KT209 TARGETING CD19, CD20, AND CD3 (CD19XCD20XCD3) DEMONSTRATED POTENT ACTIVITY IN B-CELL DISEASES WITH LOWER CYTOKINE RELEASES
Poster Number: PF369
Session: Poster Session 1
Dates: Thursday, June 11 – Friday, June 12, 2026
Highly Differentiated Preclinical Profile

The upcoming poster presentation highlights comprehensive preclinical data evaluating KT209 across in vitro, in vivo, and non-human primate (NHP) models:

Resistance-Proof Cytotoxicity: KT209 demonstrated robust clearance against both Raji and Nalm19 leukemia cells. Crucially, in Nalm19 models—which express low levels of CD20—the approved TCE glofitamab suffered a significant drop-off in efficacy, whereas KT209 maintained potent tumor-killing activity.
Decoupling Potency from Toxicity: In head-to-head human PBMC assays, KT209 demonstrated a clear trend of lower inflammatory cytokine release compared to glofitamab, successfully mitigating the primary driver of Cytokine Release Syndrome (CRS).
In Vivo Tumor Clearance: In humanized NOG mouse models, KT209 achieved potent, dose-dependent anti-leukemia activity.
Favorable NHP Safety and Tolerability: In non-human primates, a single subcutaneous dose of KT209 triggered rapid and deep peripheral B-cell depletion at the lowest tested dose. The molecule was completely well-tolerated with zero clinical adverse events and only minimal, transient cytokine release restricted to the first dose.
Leadership Commentary

John Wang, Chief Scientific Officer of Kali Therapeutics, commented:

"The data to be showcased at EHA (Free EHA Whitepaper) underscores the highly differentiated profile of KT209. By integrating dual-antigen B-cell targeting with our proprietary CD3 masking technology, we have engineered a molecule that is fundamentally more potent than currently approved TCEs in low-antigen environments, yet operates with a much wider safety window. This allows us to achieve maximum tumor attrition while strictly limiting systemic cytokine release."

Weihao Xu, Chief Executive Officer of Kali Therapeutics, stated:

"Our presentation at EHA (Free EHA Whitepaper) 2026 marks a pivotal milestone in the strategic expansion of Kali. By bringing our platform into the oncology space, we are demonstrating that our ability to safely engage T-cells is truly drug-class agnostic. The unique safety profile of our TCEs, which has already validated our autoimmune pipeline, allows us to aggressively target hematologic malignancies where tumor escape and severe CRS have historically limited patient outcomes. With KT209, we look forward to advancing into first-in-human clinical trials in Q1 2027."

About KT209

KT209 is a novel CD19 x CD20 x CD3 trispecific antibody engineered using Kali’s proprietary multi-specific antibody platform. It is designed to maximize therapeutic efficacy by simultaneously binding to two distinct B-cell antigens (CD19 and CD20) and co-engaging CD3 on T cells. This dual-targeting approach minimizes the risk of tumor escape while its unique CD3 masking design controls T-cell activation kinetics, reducing cytokine release syndrome (CRS) risks while enabling complete removal of pathogenic B-cell populations.

(Press release, Kali Therapeutics, JUN 8, 2026, View Source [SID1234666490])